Cagrilintide | 10 vials

Cagrilintide is a long-acting synthetic analogue of the naturally occurring pancreatic hormone amylin, currently in clinical development by Novo Nordisk for chronic weight management . It represents a next-generation amylin analogue designed to overcome the short half-life limitations of earlier compounds like pramlintide .

Key Specifications:

• CAS Number: 1415456-99-3

• Molecular Formula: C₁₈₇H₂₉₁N₄₅O₅₉ (approx.)

• Molecular Weight: ~4,114 g/mol

• Purity: ≥95-98% (research grade)

• Appearance: Lyophilized powder

• Storage: Store at -20°C

Mechanism of Action: Cagrilintide functions as a dual amylin and calcitonin receptor agonist (DACRA) :

• Amylin receptor (AMYR) activation: Mimics the satiety-inducing effects of natural amylin, which is co-secreted with insulin from pancreatic beta-cells

• Calcitonin receptor (CTR) activation: Contributes to metabolic regulation through complementary pathways

• Central nervous system action: Targets homeostatic and hedonic brain regions to reduce food intake

• Gastric emptying: Slows gastric emptying, contributing to reduced caloric intake

Key Research Applications:

Clinical Trial Data: In the Phase 3 REDEFINE 1 trial (N=3,417), cagrilintide 2.4 mg monotherapy demonstrated:

• 11.8% mean body weight reduction after 68 weeks (vs. 2.3% placebo)

• 31.6% of participants achieved ≥15% weight loss (vs. 4.7% placebo)

• Average weight loss of 12.5 kg compared to 2.5 kg with placebo

• Well-tolerated with mostly mild-to-moderate gastrointestinal effects

Important Notice: FOR RESEARCH USE ONLY. NOT FOR HUMAN USE, THERAPEUTIC, OR DIAGNOSTIC APPLICATIONS.

Cagrilintide is NOT FDA approved for any medical use (currently investigational). This product is intended for laboratory research purposes only.

---

Category Classification

Primary Compound Class

Cagrilintide belongs to the amylin analogue class, specifically classified as a long-acting amylin receptor agonist .

It is also classified more broadly as:

• Dual amylin and calcitonin receptor agonist (DACRA)

• Incretin mimetic (functionally related class)

• Anti-obesity peptide

Mechanism-Based Classification

Therapeutic Research Categories

Key Points

• Cagrilintide is a next-generation amylin analogue designed to overcome pramlintide's short half-life

• It works through a distinct mechanism from GLP-1 agonists, offering a complementary approach to weight management

• The peptide exhibits non-selective activation of amylin and calcitonin receptors with a unique "bypass" binding mode

• Structural features include an E14-R17 intramolecular salt bridge enhancing helical stability, and a C-terminal P37 interaction with receptor extracellular domains

• It is being developed both as monotherapy (RENEW program) and in combination with semaglutide (CagriSema)

Regulatory Status

Important Notice: FOR RESEARCH USE ONLY. NOT FOR HUMAN USE, THERAPEUTIC, OR DIAGNOSTIC APPLICATIONS